Vissza |
Wu Yi-Long; Tsuboi Masahiro; He Jie; John Thomas; Grohe Christian; Majem Margarita; Goldman Jonathan W.; Laktionov Konstantin; Kim Sang-We; Kato Terufumi; Vu Huu-Vinh; Lu Shun; Lee Kye-Young; Akewanlop Charuwan; Yu Chong-Jen; de Marinis Filippo; Bonanno Laura; Domine Manuel; Shepherd Frances A.; Zeng Lingmin; Hodge Rachel; Atasoy Ajlan; Rukazenkov Yuri; Herbst Roy S.; Kollaborációs szervezet: ADAURA Investigators; Somfay Attila; et al. (kollab. közrem.):
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer.
NEW ENGLAND JOURNAL OF MEDICINE, 383 (18).
pp. 1711-1723.
ISSN 0028-4793
(2020)
Soria Jean-Charles; Felip Enriqueta; Cobo Manuel; Lu Shun; Syrigos Konstantinos; Lee Ki Hyeong; Goeker Erdem; Georgoulias Vassilis; Li Wei; Isla Dolores; Guclu Salih Z; Morabito Alessandro; Min Young J; Ardizzoni Andrea; Gadgeel Shirish M; Wang Bushi; Chand Vikram K; Goss Glenwood D; Kollaborációs szervezet: LUX-Lung 8 Investigators; Somfay Attila; et al. (kollab. közrem.):
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
LANCET ONCOLOGY, 16 (8).
pp. 897-907.
ISSN 1470-2045
(2015)